SCHEMBL2940995

SCHEMBL2940995

COc1cc(F)c(-c2c3cccc(F)c3c(-c3c(F)c(F)c(F)c(F)c3F)c3c(F)c(F)c(F)c(F)c23)c(F)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.34
MIF P14174 1/20 0.33
RAB9A P51151 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NFE2L2 Q16236 1/20 0.32
TAAR1 Q96RJ0 1/20 0.32
TSHR P16473 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CYP1A1 P04798 2/20 0.31
CYP1A2 P05177 2/20 0.31
CYP1B1 Q16678 2/20 0.31
CDK2 P24941 1/20 0.31
FLT3 P36888 1/20 0.31
CYP2E1 P05181 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C8 P10632 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2A6 P11509 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP4B1 P13584 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2728086 0.97 ALDH1A1 (0.35) ALDH1A1MIFRAB9ASMN1; SMN2NFE2L2
SCHEMBL2939722 0.95 TSHR (0.32) ALDH1A1MIFTSHR
SCHEMBL2711131 0.94 ALDH1A1 (0.33) ALDH1A1MIFRAB9ASMN1; SMN2NFE2L2
SCHEMBL2726247 0.94 ALDH1A1 (0.34) ALDH1A1MIFRAB9ASMN1; SMN2NFE2L2
SCHEMBL2709778 0.91 NFE2L2 (0.35) ALDH1A1MIFRAB9ASMN1; SMN2NFE2L2
SCHEMBL2943542 0.91 GRM8 (0.32) CYP1A2
SCHEMBL12086127 0.91 GRM8 (0.32) CYP1A2
SCHEMBL2725617 0.90 ALDH1A1 (0.33) ALDH1A1MIFRAB9ASMN1; SMN2NFE2L2
SCHEMBL2725536 0.88 MAOA (0.35) ALDH1A1RAB9ASMN1; SMN2NFE2L2TAAR1
SCHEMBL2727335 0.88 ALDH1A1 (0.37) ALDH1A1MIFRAB9ASMN1; SMN2NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445987-B1 BLUE/VIOLET DIPHENYLANTHRACENE CHEMILUMINESCENT FLUORESCERS CYALUME TECH INC (US) 2018-05-02 EP disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
US-8257620-B2 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. (US) 2012-09-04 US disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYALUME TECHNOLOGIES, INC. 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327240-A1 Blue/violet diphenylanthracene chemiluminescent fluorescers CYP2F1, FLAD1, AFF1 ALDH1A1 34/4885MIF 3740/4885RAB9A 2786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.